Current and Future Treatment of Retinitis Pigmentosa

Cross N, van Steen C, Zegaoui Y, Satherley A, Angelillo L.

2022
Clin Ophthalmol

View publication

Therapeutic Area

Back of the eye (BOTE)
Technology

Gene / Cell Therapy
Categories

Disease understanding (epidemiology, diagnosis, QoL, Biomarkers…)

Affiliations

Market Access, Lightning Health, London, UK.; Market Access, Health Technology Assessment & Health Economics and Outcome Research, Europe, the Middle East and Africa, Santen GmbH, Munich, Bavaria, Germany

Related Publications

Efficacy and Safety of Low-Concentration Atropine in Slowing Myopia Progression in Children in Japan: The Randomized, Double-Blind Phase II/III ORANGE Study

Ohno-Matsui K., Igarashi-Yokoi T., Migita Y., Yamakawa Y, on behalf of the ORANGE study investigators

Awareness of Myopia Associated Complications and Perspectives on Myopia Management Among Parents of Children with Myopia in France and the UK

Hafizi R., Deferne N., Paudel N., Angerer A., Hsieh H.-T.

Cutamesine (SA4503) Protects Retinal Ganglion Cells in an Ocular Hypertension Model of Glaucoma Determined Using Detection of Apoptosing Retinal Cells Technology and RBPMS Cell Marker

Sharif N.A., Takashi O., Taniguchi T., Sasaoka M., Guo L., Choi S., Luong V., Cordeiro M.F.

View all Back of the eye (BOTE) publications

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022